[Seroprevalence of Mycoplasma pneumoniae in Poland in 2008-2013]

Medycyna Doswiadczalna I Mikrobiologia
|November 6, 2014
PubMed
Abstract

Insights

Mycoplasma pneumoniae infections surged in Poland during 2011-2012, with early antibodies (IgA/IgM) doubling in respiratory patients. This study tracked seroprevalence from 2008-2013, confirming an epidemic increase.

Area of Science:

  • Medical Microbiology
  • Epidemiology
  • Immunology

Context:

  • Mycoplasma pneumoniae is a leading cause of respiratory infections in children and adolescents.
  • M. pneumoniae infections exhibit epidemic patterns, occurring every 4-7 years, primarily in autumn-winter.
  • In Poland, M. pneumoniae accounts for 30-40% of bacterial respiratory infections.

Purpose:

  • To estimate the seroprevalence of Mycoplasma pneumoniae in Poland between 2008 and 2013.
  • To compare Polish seroprevalence data with that of other European countries.
  • To identify trends in M. pneumoniae infections during epidemic and non-epidemic seasons.

Summary:

  • A retrospective analysis of serological tests (ELISA) for M. pneumoniae infection was conducted on 16,825 individuals, primarily children with respiratory symptoms.
  • Early antibodies (IgA and/or IgM) for M. pneumoniae were diagnosed twice as often in autumn-winter seasons of 2011-2012 compared to 2008-2010.
  • Antibody detection rates reached 34% and 42% in the third quarters of 2011 and 2012, respectively, indicating a significant increase.

Impact:

  • The study confirms an epidemic increase of Mycoplasma pneumoniae infections in Poland during the 2011-2012 autumn-winter seasons.
  • Findings highlight the importance of serological monitoring for tracking M. pneumoniae outbreaks.
  • Results provide valuable data for public health strategies and resource allocation in managing pediatric respiratory infections.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
73
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
17
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K